Anti‐inflammatory agents, such as canakinumab in TET2‐mutated CH patients in the Canakinumab Anti‐Inflammatory Thrombosis Outcomes Study (CANTOS), may reduce CH‐related cardiovascular risk.27, 28. The gene discussed is TET2; the disease is cyclic hematopoiesis.